Browse ISCA2

Summary
SymbolISCA2
Nameiron-sulfur cluster assembly 2
Aliases ISA2; HBLD1; HesB like domain containing 1; iron-sulfur cluster assembly 2 homolog (S. cerevisiae); MMDS4; c ......
Chromosomal Location14q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion
Domain PF01521 Iron-sulphur cluster biosynthesis
Function

Involved in the maturation of mitochondrial 4Fe-4S proteins functioning late in the iron-sulfur cluster assembly pathway. May be involved in the binding of an intermediate of Fe/S cluster assembly.

> Gene Ontology
 
Biological Process GO:0006790 sulfur compound metabolic process
GO:0016226 iron-sulfur cluster assembly
GO:0031163 metallo-sulfur cluster assembly
GO:0051186 cofactor metabolic process
GO:0051188 cofactor biosynthetic process
GO:0051604 protein maturation
GO:0097428 protein maturation by iron-sulfur cluster transfer
Molecular Function GO:0005506 iron ion binding
GO:0008198 ferrous iron binding
GO:0051536 iron-sulfur cluster binding
GO:0051537 2 iron, 2 sulfur cluster binding
GO:0051539 4 iron, 4 sulfur cluster binding
GO:0051540 metal cluster binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolISCA2
Nameiron-sulfur cluster assembly 2
Aliases ISA2; HBLD1; HesB like domain containing 1; iron-sulfur cluster assembly 2 homolog (S. cerevisiae); MMDS4; c ......
Chromosomal Location14q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ISCA2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolISCA2
Nameiron-sulfur cluster assembly 2
Aliases ISA2; HBLD1; HesB like domain containing 1; iron-sulfur cluster assembly 2 homolog (S. cerevisiae); MMDS4; c ......
Chromosomal Location14q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ISCA2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolISCA2
Nameiron-sulfur cluster assembly 2
Aliases ISA2; HBLD1; HesB like domain containing 1; iron-sulfur cluster assembly 2 homolog (S. cerevisiae); MMDS4; c ......
Chromosomal Location14q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ISCA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4530.0409
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.8390.668
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1670.911
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.9190.0425
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.740.461
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.1540.392
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2850.325
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.380.73
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2280.858
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2670.844
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2880.892
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0180.771
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ISCA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolISCA2
Nameiron-sulfur cluster assembly 2
Aliases ISA2; HBLD1; HesB like domain containing 1; iron-sulfur cluster assembly 2 homolog (S. cerevisiae); MMDS4; c ......
Chromosomal Location14q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ISCA2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolISCA2
Nameiron-sulfur cluster assembly 2
Aliases ISA2; HBLD1; HesB like domain containing 1; iron-sulfur cluster assembly 2 homolog (S. cerevisiae); MMDS4; c ......
Chromosomal Location14q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ISCA2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ISCA2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolISCA2
Nameiron-sulfur cluster assembly 2
Aliases ISA2; HBLD1; HesB like domain containing 1; iron-sulfur cluster assembly 2 homolog (S. cerevisiae); MMDS4; c ......
Chromosomal Location14q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ISCA2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolISCA2
Nameiron-sulfur cluster assembly 2
Aliases ISA2; HBLD1; HesB like domain containing 1; iron-sulfur cluster assembly 2 homolog (S. cerevisiae); MMDS4; c ......
Chromosomal Location14q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ISCA2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolISCA2
Nameiron-sulfur cluster assembly 2
Aliases ISA2; HBLD1; HesB like domain containing 1; iron-sulfur cluster assembly 2 homolog (S. cerevisiae); MMDS4; c ......
Chromosomal Location14q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ISCA2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolISCA2
Nameiron-sulfur cluster assembly 2
Aliases ISA2; HBLD1; HesB like domain containing 1; iron-sulfur cluster assembly 2 homolog (S. cerevisiae); MMDS4; c ......
Chromosomal Location14q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ISCA2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.